Nicola Klein to Adolescent
This is a "connection" page, showing publications Nicola Klein has written about Adolescent.
Connection Strength
3.329
-
Incidence and Risk of Coronavirus Disease 2019 Hospitalization Among Unvaccinated Children. Influenza Other Respir Viruses. 2024 Oct; 18(10):e70022.
Score: 0.132
-
Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine. Pediatrics. 2024 Aug 01; 154(2).
Score: 0.131
-
Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
Score: 0.131
-
Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age. N Engl J Med. 2023 Dec 14; 389(24):2245-2255.
Score: 0.125
-
Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents. Pediatrics. 2023 05 01; 151(5).
Score: 0.120
-
COVID-19 vaccination protects children and adolescents. Lancet Infect Dis. 2023 01; 23(1):5-6.
Score: 0.115
-
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 04; 71(9):352-358.
Score: 0.111
-
Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season. PLoS One. 2020; 15(2):e0229279.
Score: 0.096
-
Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study. Vaccine. 2018 04 19; 36(17):2356-2363.
Score: 0.084
-
Use of acellular pertussis vaccines in the United States: can we do better? Expert Rev Vaccines. 2017 12; 16(12):1175-1179.
Score: 0.082
-
Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines. Vaccine. 2017 05 09; 35(20):2668-2675.
Score: 0.079
-
Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis. Clin Infect Dis. 2016 Dec 01; 63(11):1456-1462.
Score: 0.076
-
Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine. 2016 08 05; 34(36):4293-7.
Score: 0.075
-
Waning Tdap Effectiveness in Adolescents. Pediatrics. 2016 Mar; 137(3):e20153326.
Score: 0.073
-
Long-term immune responses to pneumococcal conjugate vaccines in children previously vaccinated with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013 Sep; 32(9):990-7.
Score: 0.061
-
Effectiveness of pertussis vaccines for adolescents and adults: case-control study. BMJ. 2013 Jul 17; 347:f4249.
Score: 0.061
-
Incidence of genital warts in adolescents and young adults in an integrated health care delivery system in the United States before human papillomavirus vaccine recommendations. Sex Transm Dis. 2013 Jul; 40(7):534-8.
Score: 0.061
-
Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics. 2013 Jun; 131(6):e1716-22.
Score: 0.060
-
Lack of association of Guillain-Barré syndrome with vaccinations. Clin Infect Dis. 2013 Jul; 57(2):197-204.
Score: 0.060
-
Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med. 2012 Dec; 166(12):1140-8.
Score: 0.058
-
Epidemiologic and clinical features of Bell's palsy among children in Northern California. Neuroepidemiology. 2012; 38(4):252-8.
Score: 0.056
-
An unmasking phenomenon in an observational post-licensure safety study of adolescent girls and young women. Vaccine. 2012 Jun 29; 30(31):4585-7.
Score: 0.056
-
Evaluation of immunization rates and safety among children with inborn errors of metabolism. Pediatrics. 2011 May; 127(5):e1139-46.
Score: 0.052
-
Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. Pediatr Infect Dis J. 2010 Jul; 29(7):613-7.
Score: 0.049
-
Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine. 2010 Jan 22; 28(4):1062-8.
Score: 0.047
-
Trends in Gonorrhea and Chlamydia Testing and Infections Across the COVID-19 Pandemic in Adolescents and Young Adults in an Integrated Health System. J Adolesc Health. 2024 Dec; 75(6):952-957.
Score: 0.033
-
Ischemic Stroke After Bivalent COVID-19 Vaccination: Self-Controlled Case Series Study. JMIR Public Health Surveill. 2024 Jun 25; 10:e53807.
Score: 0.032
-
Coronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink. Obstet Gynecol. 2024 Aug 01; 144(2):215-222.
Score: 0.032
-
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged =18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 28; 73(12):271-276.
Score: 0.032
-
Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States. MMWR Morb Mortal Wkly Rep. 2024 Feb 29; 73(8):168-174.
Score: 0.032
-
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged =18 Years - VISION and IVY Networks, September 2023-January 2024. MMWR Morb Mortal Wkly Rep. 2024 Feb 29; 73(8):180-188.
Score: 0.032
-
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023. MMWR Morb Mortal Wkly Rep. 2023 May 26; 72(21):579-588.
Score: 0.030
-
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 17; 71(53):1637-1646.
Score: 0.030
-
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 30; 71(5152):1616-1624.
Score: 0.029
-
Extended surveillance to assess safety of 9-valent human papillomavirus vaccine. Hum Vaccin Immunother. 2022 12 30; 18(7):2159215.
Score: 0.029
-
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 01; 71(13):495-502.
Score: 0.028
-
A decade of data: Adolescent vaccination in the vaccine safety datalink, 2007 through 2016. Vaccine. 2022 02 23; 40(9):1246-1252.
Score: 0.028
-
Evaluation of Trends in Homeschooling Rates After Elimination of Nonmedical Exemptions to Childhood Immunizations in California, 2012-2020. JAMA Netw Open. 2022 02 01; 5(2):e2146467.
Score: 0.028
-
The Childhood Vaccination Schedule and the Lack of Association With Type 1 Diabetes. Pediatrics. 2021 12 01; 148(6).
Score: 0.027
-
Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
Score: 0.027
-
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
Score: 0.027
-
COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021. MMWR Morb Mortal Wkly Rep. 2021 Oct 29; 70(43):1520-1524.
Score: 0.027
-
Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance - Nine States, June-August 2021. MMWR Morb Mortal Wkly Rep. 2021 09 17; 70(37):1291-1293.
Score: 0.027
-
COVID-19 Vaccination Coverage Among Insured Persons Aged =16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 16; 70(28):985-990.
Score: 0.026
-
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021 07 15; 385(3):239-250.
Score: 0.026
-
Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination. Vaccine. 2021 06 16; 39(27):3614-3620.
Score: 0.026
-
Temporal Trends in Undervaccination: A Population-Based Cohort Study. Am J Prev Med. 2021 07; 61(1):64-72.
Score: 0.026
-
Evaluating the Association of Stillbirths After Maternal Vaccination in the Vaccine Safety Datalink. Obstet Gynecol. 2020 12; 136(6):1086-1094.
Score: 0.025
-
SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics - Eight U.S. Health Care Centers, March 1-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 23; 69(38):1355-1359.
Score: 0.025
-
Epidemiology and Clinical Outcomes of Hospitalizations for Acute Respiratory or Febrile Illness and Laboratory-Confirmed Influenza Among Pregnant Women During Six Influenza Seasons, 2010-2016. J Infect Dis. 2020 04 27; 221(10):1703-1712.
Score: 0.024
-
Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics. 2019 12; 144(6).
Score: 0.024
-
Uptake and safety of hepatitis A vaccination during pregnancy: A Vaccine Safety Datalink study. Vaccine. 2019 10 16; 37(44):6648-6655.
Score: 0.023
-
Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15. Vaccine. 2019 10 16; 37(44):6673-6681.
Score: 0.023
-
Incidence of Herpes Zoster Among Children: 2003-2014. Pediatrics. 2019 07; 144(1).
Score: 0.023
-
Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study. Vaccine. 2018 10 01; 36(41):6111-6116.
Score: 0.022
-
Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. BMC Pulm Med. 2017 Dec 16; 17(1):208.
Score: 0.021
-
Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine. Vaccine. 2017 12 14; 35(49 Pt B):6879-6884.
Score: 0.020
-
Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy. Obstet Gynecol. 2017 09; 130(3):599-608.
Score: 0.020
-
Maternal Tdap vaccination and risk of infant morbidity. Vaccine. 2017 06 22; 35(29):3655-3660.
Score: 0.020
-
No association between influenza vaccination during pregnancy and adverse birth outcomes. Vaccine. 2017 05 31; 35(24):3186-3190.
Score: 0.020
-
Identifying birth defects in automated data sources in the Vaccine Safety Datalink. Pharmacoepidemiol Drug Saf. 2017 Apr; 26(4):412-420.
Score: 0.019
-
Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013. Vaccine. 2016 Feb 10; 34(7):968-73.
Score: 0.018
-
Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011. Vaccine. 2016 Jan 02; 34(1):167-71.
Score: 0.018
-
Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy. Obstet Gynecol. 2015 Nov; 126(5):1069-74.
Score: 0.018
-
Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. JAMA. 2015 Oct 20; 314(15):1581-7.
Score: 0.018
-
Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016 Mar; 137(3):868-78.
Score: 0.018
-
An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J. 2015 Sep; 34(9):983-91.
Score: 0.018
-
Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA. 2014 Nov 12; 312(18):1897-904.
Score: 0.017
-
Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink sites. Prev Med. 2014 Oct; 67:316-9.
Score: 0.016
-
Live vaccine use and safety in DiGeorge syndrome. Pediatrics. 2014 Apr; 133(4):e946-54.
Score: 0.016
-
Vaccinations given during pregnancy, 2002-2009: a descriptive study. Am J Prev Med. 2014 Feb; 46(2):150-7.
Score: 0.016
-
Cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ: comparison of ICD-9 codes and pathology results--Kaiser Permanente, United States, 2000-2005. Cancer Epidemiol Biomarkers Prev. 2013 Jun; 22(6):1129-32.
Score: 0.015
-
Clinical assessment of serious adverse events in children receiving 2009 H1N1 vaccination. Pediatr Infect Dis J. 2013 Feb; 32(2):163-8.
Score: 0.015
-
Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact. Cancer Causes Control. 2013 Feb; 24(2):403-7.
Score: 0.015
-
Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2012 Nov 26; 30(50):7253-9.
Score: 0.014
-
Immunization and Bell's palsy in children: a case-centered analysis. Am J Epidemiol. 2012 May 01; 175(9):878-85.
Score: 0.014
-
Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med. 2012 Feb; 271(2):193-203.
Score: 0.014
-
Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011 Oct 26; 29(46):8279-84.
Score: 0.013
-
Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. Vaccine. 2011 Oct 26; 29(46):8302-8.
Score: 0.013
-
Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of age. Vaccine. 2011 Sep 02; 29(38):6592-7.
Score: 0.013
-
Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. Pediatrics. 2011 May; 127 Suppl 1:S54-64.
Score: 0.013
-
Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009 Oct; 99 Suppl 2:S389-97.
Score: 0.012
-
Varicella vaccination and ischemic stroke in children: is there an association? Pediatrics. 2009 Feb; 123(2):e228-34.
Score: 0.011